Momentum Trades

MomentumOptionsTrading.com Weekly Wrap for 2/16/2014

MomentumOptionsTrading.com Weekly Wrap for 2/16/2014

11:30pm (EST)

 

1.  Market Summary

2.  Cytokinetics (CYTK) Trying to Right the Ship

3.  Earnings

4.  Weekly Wrap Portfolio Update 

5.  Week Ahead

 

(To view the charts, please log into the Members Area and go to the Weekly Wrap Premium section.)

 

= = = = = = = = = = = = = = =

 

1.  Market Summary  

“The bulls needed to get off to a good start for the week but Monday’s (and Friday’s) have belonged to the bears so the odds weren’t good.  We mentioned February would be a tricky month to trade and the first week made Wall Street’s head spin.

The Dow fell 358 points to its midweek low before surging 458 points to end the week with nearly a triple-digit gain.  The 816 point move represented a 5% one-week swing.  The S&P 500 came within spitting distance of triggering 1,800 after making a 45-point swing, or nearly 3% from the low to the high.

The suit-and-ties came into the week worried about the Chinese markets and the Lunar New Year, the Japanese market that was in bear market territory, the opening of the Sochi Olympics, and the Nonfarm Payroll report.  Oh, and the debt-ceiling debate.

The dark clouds hanging over these events got stormy but suddenly seemed to clear following the snapback rally.  The suit-and-ties that were calling for the magical 10% correction and suggested staying short quickly had changed their minds by Friday’s close.

China’s market reopened without a hitch and Japan’s Nikkei also made a strong comeback off their lows.  The Sochi Olympics have been uninterrupted although there have been some more serious “incidents” besides the roaming dogs and Bud Light looking drinking water.

As far as the debt-ceiling, Treasury Secretary Jack Lew warned the zombies and the White House that the Treasury would run out of cash by the end of the month.  The Republicans (and Democrats) can’t afford another government shutdown as they are trying to gain (or keep) control of the Senate.  Both sides might throw some punches but most economists believe the zombies will once again kick the can down the road and avoid a default.

The Nonfarm Payrolls were debated all day and the zombies did their best to convince Wall Street it was a “good” number.  The 113,000 jobs number was “better” than December’s print of 75,000 that were “revised” by just 1,000 but the the labor force participation rate dropped to a 35 year low.  The funny numbers we often mention the zombies report can be debated but this fact cannot as the unemployment rate FELL to 6.6%.

This puts the Fed within their 6.5% targeted rate for a continuation of taper cuts but the market may have rallied on hopes the Fed might stop tapering.  This could be a dangerous game the bulls are playing with Janet Yellen speaking on Tuesday.  This will be her first testimony to Congress on the state of the economy and her comments could seriously impact the market for better or worse.

The technical picture did seem to change in 48 hours but the one warning sign is that it came on low volume.  We covered the “December Low Indicator” last week for the Dow and while the S&P 500 ended the week higher, it also breached its December low of 1,767.

The current action is suggesting another 2%-3% possible upside for February but we believe March could be full of earnings warnings as companies blame the weather.  4Q earnings will be winding down following the busiest two weeks of the season and major Tech and blue-chips have already reported.  There will still be plenty of possible earnings trades over the next few weeks but analysts are already looking ahead.

One sector we will be watching for a continued run higher are the Financial stocks.  The Financial Select Spiders (XLF, $21.29, up $0.26) will need to clear $21.50 and the 50-day MA to keep the momentum going.  We could long if this level is cleared by using the March 22 calls (XLF140322C00022000, $0.18, up $0.06) as a cheap way to play continued strength.  A drop below $20.50 would be bearish.

XLF21714

We have been analyzing the 10 and 15-year charts for the indexes over the past few weeks and we will be making our annual yearend predictions next weekend.  This week should give us the clues we need to see if a continued rally is in store or if lower lows are on tap.”  (from 2/9/2014 Weekly Wrap…)

The market continued its incredible comeback as the bulls quieted talk of an impending collapse by rallying back to prior resistance and January highs.

The action for February has been breathtaking to say the least and has Wall Street frustrated.  The bears used the last 5 trading sessions in January and the first 3 of this month to push November lows while the bulls have used the last 8 trading days to push January and new highs.

The results have produced mixed returns for the year but it appears as though the bulls could push record highs again before the speed bumps turn into possible potholes down the road.  (continued…)

The Dow dashed 126 points higher, or 0.8%, to settle at 16,154 on Friday.  The blue-chips made a slight dip to 15,733 to start the week but support at 15,600 easily held before the index ended Monday with a gain of 7 points.  It wasn’t much but the close above 15,800 to 15,801 was significant.  We said to expect a run to 16,000-16,200 once cleared and Tuesday’s high reached 16,027 before the close at 15,994.  Wednesday produced a higher high at 16,036 but the Dow finished the session lower and closed at 15,963. Thursday’s run to 16,039 came after a triple-digit decline to 15,863 but the bulls cleared 16,000 with the finish at 16,027.  Friday’s high reached 16,175 and cleared the 50-day MA (16,096).  A close above 16,200 gets 16,350 in play with a run to 16,500-16,600 possible on continued momentum.  The all-time high for the Dow is 16,588.  Support will try to hold at 16,000 on any pullback with 15,800 and the 100-day MA serving as backup.  For the week, the Dow surged 360 points, or 2.3%, after starting at 15,794 but is down 422 points, or 2.6%, for 2014.

DOW21714

The S&P 500 jumped 9 points, or 0.5%, to end at 1,838.  The index tested a low of 1,791 on Monday but easily held 1,775 before closing 2 points higher to 1,799.84.  Although the close just missed 1,800 the high at 1,799.94 was a pretty good clue the bulls would clear resistance and make a run at the 50-day MA (1,811).  We mentioned 1,810 was more important than a close above 1,800 as it would lead to 1,825-1,850.  Tuesday’s peak reached 1,826 and the close at 1,819 was bullish following the perfect back test to 1,800.  Wednesday’s low was 1,815 and was another good clue higher highs would come after the 50-day MA held and a flat finish.  Thursday’s run touched 1,830 with a close at 1,829 and above 1,825.  Friday’s high reached 1,841.  A close above 1,850 would rekindle our 1,875-1,900 fluff targets from December.  The bulls have 3 strikes down to 1,825; 1,810; and 1,800 and then it would be the bears turn to bat again.  The S&P 500 came into the week at 1,797 and added 41 points, or 2.3%, by Friday’s close.  For the year, the index is lower by 10 points, or 0.5%.

SPX21714

The Nasdaq added 3 points, or 0.1%, to finish at 4,244.  Tech’s strength on Monday was also a good sign after the bears shot a 3-pointer to 4,122 and but it was really a brick as 4,125 held. The index rebounded to push 4,148.30 and came close to clearing 4,150.  We mentioned the next 50-points could determine the next trend and Tuesday’s pop to 4,198 left little doubt the bulls would clear 4,200 again.  Wednesday’s close at 4,201 made us look like a Guinness (brilliant!) as we said it would open the doors for a possible hop to 4,400-4,500 on continued strength.  These were also our December fluff targets.  Believe it or not, Tech closed at fresh 13-year highs after clearing its January 22 close of 4,243.  The intraday kiss of 4,250 also represented new bull territory.  Near-term support is at 4,200 and then 4,150-4,100.  The Nasdaq was at 4,125 and advanced 119 points, or 2.9%, and is UP 68 points, or 1.6%, year-to-date.

NAS21714

The Russell 2000 gained 1.5 points, or 0.01%, to close at 1,149.21.  The small-caps traded down to 1,109 on Monday’s open but closed with a 2-point win and above the 100-day MA.  We said this was a bullish sign but that 1,125 needed to clear to trigger 1,150.  Tuesday’s run reached 1,131 before ending at 1,129 while Wednesday’s intraday high reached 1,137 with a close at 1,132.  Thursday’s dip to 1,124.40 tested support before a surge to 1,147 into the closing bell.  Friday’s high reached 1,149.90.  We mentioned a close above 1,150 could led to 1,175 – and possibly 1,200 which was triggered in December before being erased.  The Russell came into Monday’s open at 1,116 and zoomed 33 points, or 2.9%, for the week and is showing a decline of 14 points, or 1.2%, YTD.

RUT21714

The S&P 500 Volatility Index ($VIX, 13.57, down 0.57) came into the week just above 15 and we talked about the bulls needing to get below this level to confirm the next leg higher.  The bears needed to crack 17.50 but did no damage on Monday’s open as the high only reached 15.76.  The VIX ended the session slightly lower at 15.26 and it also looked like a bullish sign as the bears failed to take advantage of the weakness.  Tuesday’s low reached 14.08 and the bulls got their close below 15 to 14.51.  Rally on.  Wednesday’s test to 14.02 also ended with a lower finish to 14.30.  Thursday’s test to 13.98 and lower close to 14.14 set up Friday’s dip to 13.44 and the next wave of support.  If the bulls can get below 13.50 on a close, the VIX could test 11 and fresh 52-week LOWS.  Any pops back above 15 could signal another top is in.

VIX21714

Last week’s homework showed a perfect back test to the downside channels we highlighted in our chart work and mentioned there could be an upside move of 2%-3% on a continued rebound.  Friday’s closes were right where we expected them to be and the VIX is also confirming the bullish action.

The push towards all-time highs again would require another 1%-2% run and our prior fluff targets from December could come into play on continued strength.

The nasty 8% drop to support to start the month has all been forgotten for the most part as the indexes moved back into their prior 6-week trading ranges.  We often say trading ranges can get “stretched” but the break below multiple layers of support was swift and fast.  The rally back towards records highs has also been breathtaking.

February is always tricky to trade and we mentioned it was the weakest month of the seasonal bull runs from November thru April.  This February has been especially volatile as there were numerous headwinds the market faced but we mentioned last week they were suddenly clearing up.

We touched on the weather and the impact it would have on economic news and earnings going forward and the trick is to figure if this news is already factored into the market or if it will hinder the indexes for the remainder of the first quarter.

The Nasdaq is at fresh 13-year highs and the S&P 500 is on the verge of triggering new all-time highs (less than 1% away).  The Dow is a little more than 2% from ringing the all-time high bell and the Russell 2000’s “official” intraday all-time high is 1,182.04 set on January 22, 2014.  This would require a 3% move by the small-caps and a 5% move clears 1,200.

A 5% move in the Dow from current levels would mean 17,000; the S&P 500 would be above 1,900 to 1,925; and the Nasdaq would be near 4,475 and pushing 4,500.  These levels are right at our December fluff targets, imagine that.

We wanted to mention the Russell’s move in December one last time for the stock market conspiracy theorists:

From our December 24, 2013 Daily Update:

We mentioned the spike in the Russell 2000 was puzzling and from our research it was the result of a “temporary technical issue” in the index’s data feed for real-time index calculations.  The issue was supposedly “fully resolved” and the high of 1213.49 was to be corrected after Monday’s closing bell according to the higher ups familiar with the situation.

RUTb21714

We will check the Russell’s chart throughout the week to see if there is a correction or it is stands.

There have been a number of these types of occurrences over the past few months and it could be a prelude to what lies ahead.  We reported the strange VIX move that occurred a few weeks ago and the overnight reversal of futures on the prior Monday (December 16).  These strange moves in futures, the VIX, and now the Russell could be warning signs that more rocky moves and volatility could be ahead.”  (END)

We wanted to mention this again because the Historical Prices in Yahoo Finance have also been “corrected” as it now shows an intraday high of 1,157.34 with a close of 1,157.22 for December 23, 2013.

This was the spot we wanted to do our yearend predictions but we need to see how this week plays out as there are still some technical charts we are looking at that are incomplete.  There is also one earnings report we want to watch and digest this week and that is Wal-Mart Stores (WMT, $75.79, up $0.43).  While the 4Q numbers will certainly move the stock, we are more interested in the current quarter.  The company should offer a great (or discouraging) outlook for 1Q earnings as the reporting season starts in mid-April.

The market could stay steady through the end of February but March is setting up to be a battle as 1Q earnings warnings (or upgrades) start trickling in.  The zombies said the weather wasn’t a factor in the unemployment numbers but many companies that believe they will miss Wall Street’s numbers will use weather as the number one reason.

We expect a busy week with possible New Trades and Profit Alerts so check your email inboxes frequently and we will do our best to let you know when possible new trades will be coming out (see Watch List in Daily and Earnings section in Weekly Wrap).

As we head to press, futures are showing a higher open to start the week:  Dow futures are up 36 points to 16,163 while the S&P 500 futures are higher by 3 points to 1,838.  The Nasdaq 100 futures are advancing 6 points to 3,669.

 

= = = = = = = = = = = = = = =

 

2.  Cytokinetics (CYTK) Trying to Right the Ship 

By Michael Bryant

 

Key of Technicals Used In Following Articles

Charta8512

Cytokinetics (CYTK, $9.50, up $0.38) has had a long and difficult road, but things seem to be turning brighter for the company.

Charta21714

Born in Illinois at the end of the Great Depression, founder James Spudich was fascinated with chemistry and studied bioluminescence at the University of Illinois, where he earned a B.S. in chemistry in 1963.  He then went on to receive a Ph.D. in biochemistry from Stanford University in 1968, and did postdoctoral work at Stanford from 1968 to 1969 and at the MRC Laboratory of Molecular Biology at Cambridge University from 1969 to 1971.  His research focused on how the protein motor myosin drives cell movement, cytokinesis, and muscle contraction.  The fibrous protein myosin forms the contractile filaments of muscle cells.  Further, myosin helps regulate cytokinesis, the process in which the cytoplasm of a single eukaryotic cell is divided to form two daughter cells.

Fellow Stanford researcher Ron Vale was also focused on molecular motors, but he primarily studied a protein motor called a kinesin.  The movement of kinesins supports mitosis, meiosis, and transport of cellular material.  Both mitosis and meiosis are the duplication of genetic material among two like daughter cells.  Meanwhile, Larry Goldstein was the first scientist to identify and characterize kinesin genes.  In August 1997, Spudich teamed up with Goldstein, Vale, and James Sabry to form Cytokinetics to maximize the cytoskeleton for drug discovery and develop methods for storing, retrieving, organizing, and analyzing biological data.

The company’s early days seemed promising.  In the first three years, it had managed to get a total of $75.0 million in financing from investors including Vulcan Ventures, Duke University, and CSFB Private Equity.  On June 25, 2001, the company formed a collaborative agreement with GlaxoSmithKline (GSK) to develop small molecule therapeutics targeting and inhibiting mitotic kinesins for applications in the treatment of cancer and other diseases.  Glaxo agreed funding of approximately $50 million over the minimum 5-year research term, including a $14 million upfront cash payment, a $14 million purchase of Cytokinetics preferred stock, plus any milestone payments.  The company received its first milestone payment of $2 million in September of that year.

On April 29, 2004, the company sold 6.9 million shares to the public at $13 per share, above the expected $12 price and raising $89.7 million.  Shares began trading on the Nasdaq National Market under the ticker CYTK at $14.50 and closed at $16.10.  However, the road has been largely downhill since.  Shares peaked at $17.90 on May 5th, and then started falling.  The stock had a short pop when it partnered with biotech giant Amgen (AMGN) in 2007 to develop small molecule therapeutics that activate cardiac muscle contractility for potential applications in the treatment of heart failure.  Rumors developed of a merger, but the companies have denied such claims.  But in 2009, Glaxo parted ways with the company.  Shares plunged 17%.

Chartb21714

Named COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), the trials are expected to be complete in the first half of this year.  The company completed its Phase IIb trial ATOMIC-AHF (A Trial of Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) back in August of last year.  However, the stock plunged as the company reported that the trial had missed its primary endpoint in two of the three groups.  But investigators were upbeat, as the third group showed promise for a Phase III trial.

The company is also developing Tirasemtiv and CK-2127107, which are skeletal muscle activators, as potential treatments for diseases and medical conditions associated with aging, muscle wasting, or neuromuscular dysfunction.  Tirasemtiv (CK-2017357) is in Phase IIb clinical trials program and has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment.  Data from this Phase IIb clinical trial are expected in the April of 2014.  As for its CK-2127107, which it is developing with Astellas Pharma (ALPMY), it had released positive Phase I data in April of 2013 for the drug which treats muscle loss.

On January 13th, there was over 3,400 May 10 calls purchased.

The stock surged 26% on Friday, February 7th after the company reported 4th quarter results.  Revenue increased to $24.3 million from $2.2 million in the same quarter a year ago, boosted by license / research and development revenues of $17.2 million from Amgen and $6.5 million from Astellas Pharma.  Earnings increased to $0.21 per share compared to earning of -$0.48 per share in the same period a year ago.  The next earnings report will not be until April 28th.

The company expects cash revenue of $19 million to $21 million for 2014.  The guidance does not include approximately $10 million deferred revenues, $3 million stock compensation expense, and potential milestone payments it may receive from partners.  Additionally, the company expects research and development expenses of $50 to $53 million and general /administration expenses of $15 to $17 million.  Based on its guidance, it could burn through approximately $46.5 million in cash in 2014.  Cash, cash equivalents, and investments totaled $80.2 million as of December 31, 2013.

Chartc21714

At $9.50, the stock is way below its low target of $20.00 made by the 6 analysts recorded by Thomson/First Call.  Mean target is $23.33, median target of $23.50, and high target is $26.00.  Using a scale of 1.0 as a strong buy and 5.0 as a sell, the average rating of the stock was 1.7, unchanged from a week ago.

 

Current Month

Last Month

Two Months Ago

Three Months Ago

Strong Buy

2

2

2

2

Buy

5

5

5

5

Hold

0

0

0

0

Underperform

0

0

0

0

Sell

0

0

0

0

Chartd21714

 

= = = = = = = = = = = = = = =

 

3.  Earnings  

The companies in BOLD, we are looking at as possible trades and we may list call or put options on them in our Daily Newsletter.  If they become official recommendations, we sent out Trade Alerts or include them in our 9am and 1pm updates that come out during the week (Quotes are from 2/14/14 close)

By Catherine Tierney

 

Tuesday afternoon

Analog Devices (ADI

Herbalife (HLF)

 

La-Z-Boy (LZB, $27.44, up $0.09)

February 25 puts (LZB140222P00025000, $0.45, flat)

March 30 calls (LZB140322C00030000, $0.55, flat)

Thoughts:  We are bullish on the stock but we don’t trust it enough without insurance.

LZB21714

Nabors Industries (NBR)

 

NPS Pharmaceuticals (NPSP, $37.03, down $1.27)

February 40 calls (NPSP140222C00040000, $0.90, down $0.20)

Thoughts:  Shares could be on the verge of a breakout.  This is a huge risk/ reward if shares can clear $40.  If not the calls will likely expire worthless.

NPSP21714

Panera Bread (PNRA)

Photronics (PLAB)

 

Potbelly (PBPB)

PBPB21714

 

Wednesday morning

Cinemark (CNK)

 

Garmin (GRMN)

GRMN21714

Lumber Liquidators (LL)

 

MGM Resorts International (MGM)

MGM21714

Six Flags (SIX)

 

Wednesday afternoon

Avis Budget Group (CAR)

Crocs Inc. (CROX)

Denny’s (DENN)

HomeAway (AWAY)

Jack in the Box (JACK)

LifeLock (LOCK)

Millennial Media (MM)

Rubicon Technology (RBCN)

Safeway (SWY)

Tesla Motors (TSLA)

Veeco Instruments (VECO)

 

Thursday morning

Alkermes, Inc. (ALKS)

Cyberonics Inc. (CYBX)

Exact Sciences (EXAS)

Sonus Networks (SONS)

Toro (TTC)

Walter Industries (WLT)

 

World Wrestling Federation (WWE, $23.50, up $0.60)

March 25 calls (WWE140322C00025000, $1.30, up $0.05)

Thoughts:  We like this stock for a run past $25 on better-than-expected earnings.  However, they are still a little expensive and may keep us on the sidelines.

WWE21714

 

Thursday afternoon

Aruba Networks (ARUN)

Express Scripts (ESRX)

 

Groupon (GRPN, $10.51, down $0.25)

February 11 calls (GRPN140222C00011000, $0.51, down $0.13)

March 11 calls (GRPN140322C00011000, $0.77, down $0.12)

Thoughts:  Shares could make a run to $12 on a blowout quarter, if the company misses expectations shares could easily fall below $10.

GRPN21714

Hewlett-Packard (HPQ)

Pilgrim’s Pride (PPC)

Public Storage, Inc. (PSA)

Rocket Fuel (FUEL)

 

WebMD Health Corp (WBMD)

WBMD21714

 

Friday Morning

Boise Cascade (BCC)

Charter Communications (CHTR)

Ruths Chris Steak House (RUTH)

Starz – Liberty Capital (STRZA)

Strayer Education (STRA) 

 

= = = = = = = = = = = = =

 

3.  Weekly Wrap Covered Call Portfolio Update (Closing prices as of 2/14/14)

Our Weekly Wrap Closed Trade Track Record for 2014 is 8-1 (93-8, overall since the start of 2011). 

 

Galena Biopharma (GALE, $3.73, down $0.63) LEAP Trade

October 7 calls (LEAPs) (GALE141017C00007000, $0.60, down $0.25)

Original Entry Price:  $1.15 (2/10/13)

Exit Target:  $2.30

Return:  -48%

Stop Target:  None

 

Galena Biopharma (GALE, $3.73, down $0.63) Stock Trade

Original Entry Price:  $5.17 (2/10/14)

Lowered Price from Selling Options:  $5.17

Exit Target:  $10

Return:  -28%

Stop Target:  $2.50

Action:  We were totally caught off-guard by the news on Galena midweek but we didn’t want to panic until we did some research.  The close above $5 and the 50-day MA looked extremely bullish until new broke the company paid a “Dream Team” to promote the company’s stock.

Support is at $3 and the 200-day MA.  We are going to set a soft stop at $2.50, or exit target, that could become a Hard Stop if shares fall below $3.  We would like to see a close back above $4 to start the week after the company released this statement on Friday:

“Dear Shareholders: Due to the recent media attention on Galena Biopharma that we acknowledge is having an impact on investor confidence, we felt it necessary, as a service to our shareholders, to publicly respond to the discussions and set the record straight. The genesis of this attention is due to a single reporter, Adam Feuerstein from TheStreet.com, who clearly has an agenda when it comes to Galena. This can be evidenced by his numerous, tabloid-like articles on the company that have appeared over the past three years and are sensational but largely devoid of true information. The article this week is just another in the line, which for us have become noise. Mr. Feuerstein has never requested a meeting with the company to understand the details of our programs or the goals of the company. On the contrary, his requests for information are consistently accusatory and negative. As a result, we do not feel it is worthwhile to engage him or respond to other media outlets that serve to advance his agenda. However, we do recognize that you, our shareholders, deserve a direct response on the matters at hand. The only facts in Mr. Feuerstein’s most recent article that are remotely accurate are that Galena previously engaged the DreamTeamGroup and that insiders at the company, including me, divested shares in mid January. All other accusations in this article – as with his prior reporting on Galena – are specious and conveniently arranged to create controversy. (END)

If we take any action this week, or close the trade, we will send out a Trade Alert.  Otherwise, continue to hold.

 

Discovery Laboratories (DSCO, $2.26, down $0.05) Stock Trade

Original Entry Price:  $2.42 (1/7/14)

Lowered Price from Selling Options:  $2.42

Exit Target:  $4.50-$5

Return:  -7%

Stop Target:  $1

 

Discovery Laboratories (DSCO, $2.26, down $0.05) Covered Call Stock/ Option Trade

Sold April 3 calls (DSCO140419C00003000, $0.15, flat)

Original Entry Price:  $2.42 (1/7/14)

Lowered Price from Selling Options:  $2.17

Exit Target:  $4.50-$5

Return:  4%

Stop Target:  $1

Action:  Shares are trapped between the 50-day and 100-day MA’s after reaching a high of $2.34 throughout the week, including Friday.  We have been mentioning the next level of resistance is at $2.30-$2.40 and a move above $2.50 should trigger $3.  Support is at $2.20 with backup at $2.10.

DSCO21714

On 1/7/2014 we recommended buying shares at $2.42 and selling the April 3 calls for 25 cents to lower our cost basis to $2.17.  If we are called away in mid-April at $3 the trade will make 39%. 

 

Opko Health (OPK, $8.49, up $0.10) LEAP Option Trade

March 10 calls (OPK140322C00010000, $0.15, flat) LEAP OPTION

Original Entry Price:  $0.70 (12/17/13)

Exit Target:  $1.40-$2.10

Return:  -71%

Stop Target:  None

Action:  Shares held support at $7.75-$7.50 before Thursday’s surge back above $8.  The high checked-in at $8.47 and the test to the 200-day MA was bullish.  Friday’s high reached $9.07 with a close right on the 200-day MA.  The 50-day MA at $8.75 is near-term resistance and a close above this level should get $9-$9.50 in play this week.  Our breakeven point on the trade is $10.70 by the third week of March and the stock is capable of making huge moves.

OPK21714

H&R Block (HRB, $31.07, up $0.34)

April 32 calls (HRB140419C00032000, $1.05, up $0.10) LEAP Option

Original Entry Price:  $0.95 (11/5/13)

Exit Target:  $1.90+

Return:  11%

Stop Target:  None

Action:  We have a near-term target of $32 with fluff up to $34-$36.  Support is at $30-$29.50.  There could be a major breakout if $31.63 clears as it represents 52-week and all-time highs.  The company could also announce the sale of its bank unit over the near-term that will likely boost shares 3%-5% one a deal is announced.  There are a half-dozen bidders in conversation with the Block and could be the catalyst to carry shares to the mid-$30’s.

HRB21714

Pizza Inn Holdings (PZZI, $6.50, up $0.15) Stock Trade

Original Entry Price:  $8.10 (10/11/13)

Lowered Price from Selling Options/ Dividends:  No options available

Exit Target:  $12+

Return:  -20%

Stop Target:  $7

Action:  Pizza Inn tested lows of $5.60 and $5.64 on Tuesday and Thursday.  This is signaling near-term support at $5.50 but shares had daily closes above $6.  Resistance is at $6.75-$7 and a close above the latter would be bullish.

The company has 150 Pie Five shops opening this year and is expanding rapidly.  We believe this will be a $15-$20 stock in 1-2 years and insiders and mutual funds own nearly 40% of the company.

PZZI21714

Sonus Networks (SONS, $3.17, up $0.02)

Original Entry Price:  $3.73 (9/9/13)

Lowered Price from Selling Options:  $3.73

Exit Target:  $5

Return:  -15%

Stop Target:  $2.50

Action:  Earnings are due out this week.  Shares held near-term support at $3 all week following a test to $2.98 on Monday.  We mentioned a close above above $3.10 and the major moving averages (100 & 200) would be bullish and Tuesday’s close at $3.11 was just what we wanted to see.  We are expecting a 10% move on Thursday’s earnings announcement.  Analysts are expecting a profit of 2 cents a share on revenue of $72.5 million.

SONS21714

DryShips (DRYS, $3.70, down $0.03)

Original Entry Price:  $5.25 (1/3/11)

Lowered Price from Selling Options:  $4.60

Exit Target:  $6, lower to $5

Return:  -20%

Stop Target:  $2

Action:  Support at $3.50 and the 100-day MA held to start the week with shares making a run at $4 on Tuesday.  Shares are now battling the 50-day MA and a close above this level and then $4 would get us looking at writing another call option.  This is one of our current longest running trades so we are also looking to exit for a small profit as soon as we can as we feel there are better opportunities elsewhere.

DRYS21714

Trades on HOLD (6):  AKS Steel Holding (AKS), Rambus (RMBS), Bebe Stores (BEBE), Vivus (VVUS), Dendreon (DNDN)

Millennial Media February 10 calls (from October 2013) LEAP Option – Earnings are due on Wednesday and we will need a run past $10 on the February calls to breakeven.

 

= = = = = = = = = = = = = = =

 

4.  Week Ahead 

Here is a chart of the events for the week ahead:

ECOcal21714

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Scroll to Top